$ASMB
Assembly Biosciences Inc

2017 Q2 Form 10-Q Financial Statement

#000114420417024996 Filed on May 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $2.359M $50.00M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.800M $4.040M $3.160M
YoY Change 29.25% 27.85% -6.23%
% of Gross Profit
Research & Development $12.13M $10.57M $8.120M
YoY Change 61.26% 30.17% 111.77%
% of Gross Profit
Depreciation & Amortization $50.91K $31.92K $18.56K
YoY Change 182.86% 71.98% 33.47%
% of Gross Profit
Operating Expenses $12.13M $14.61M $11.28M
YoY Change 61.26% 29.52% 194.18%
Operating Profit -$13.57M -$13.93M
YoY Change 29.78%
Interest Expense -$100.0K $0.00 $290.0K
YoY Change -133.33% -100.0% 383.33%
% of Operating Profit
Other Income/Expense, Net -$101.1K -$764.00
YoY Change -133.49%
Pretax Income -$13.67M -$13.93M -$10.99M
YoY Change 34.63% 26.75% 53.92%
Income Tax -$69.51K
% Of Pretax Income
Net Earnings -$13.60M -$13.93M -$10.99M
YoY Change 33.95% 26.78% 53.79%
Net Earnings / Revenue -576.4% -27.86%
Basic Earnings Per Share
Diluted Earnings Per Share -$784.3K -$806.6K -$637.8K
COMMON SHARES
Basic Shares Outstanding 17.35M shares 17.27M shares 17.23M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.60M $90.90M $58.30M
YoY Change 19.06% 55.92% -39.33%
Cash & Equivalents $39.45M $70.82M $20.40M
Short-Term Investments $36.10M $20.10M $37.90M
Other Short-Term Assets $1.000M $1.300M $800.0K
YoY Change 66.67% 62.5% 181.85%
Inventory
Prepaid Expenses
Receivables $1.114M
Other Receivables $0.00
Total Short-Term Assets $77.70M $92.20M $59.10M
YoY Change 21.22% 56.01% -38.65%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $200.0K $100.0K
YoY Change 0.0% 100.0% -42.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.300M $200.0K $23.60M
YoY Change -71.05% -99.15% 23500.0%
Other Assets
YoY Change
Total Long-Term Assets $45.10M $42.10M $65.40M
YoY Change -15.07% -35.63% 55.85%
TOTAL ASSETS
Total Short-Term Assets $77.70M $92.20M $59.10M
Total Long-Term Assets $45.10M $42.10M $65.40M
Total Assets $122.8M $134.3M $124.5M
YoY Change 4.78% 7.87% -9.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $700.0K $1.900M $2.300M
YoY Change -70.83% -17.39% 76.92%
Accrued Expenses $6.300M $4.000M $1.200M
YoY Change 142.31% 233.33% 36.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.00M $11.00M $3.600M
YoY Change 140.0% 205.56% 69.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $43.10M $44.30M
YoY Change
Total Long-Term Liabilities $43.10M $44.30M $0.00
YoY Change 271.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.00M $11.00M $3.600M
Total Long-Term Liabilities $43.10M $44.30M $0.00
Total Liabilities $66.20M $66.40M $15.20M
YoY Change 298.8% 336.84% 10.95%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $56.50M $67.90M $109.3M
YoY Change
Total Liabilities & Shareholders Equity $122.8M $134.3M $124.5M
YoY Change 4.78% 7.87% -10.01%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$13.60M -$13.93M -$10.99M
YoY Change 33.95% 26.78% 53.79%
Depreciation, Depletion And Amortization $50.91K $31.92K $18.56K
YoY Change 182.86% 71.98% 33.47%
Cash From Operating Activities -$12.35M $34.94M -$9.210M
YoY Change 82.42% -479.42% 150.72%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $2.163K
YoY Change -100.0% -92.96%
Acquisitions
YoY Change
Other Investing Activities -$19.12M $6.660M $2.500M
YoY Change -384.95% 166.4%
Cash From Investing Activities -$19.12M $6.658M $2.500M
YoY Change -384.95% 166.32% -8240.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 110.0K $640.0K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -12.35M $34.94M -9.210M
Cash From Investing Activities -19.12M $6.658M 2.500M
Cash From Financing Activities 110.0K $640.0K 0.000
Net Change In Cash -31.36M $42.24M -6.710M
YoY Change 52166.67% -729.55% -110.02%
FREE CASH FLOW
Cash From Operating Activities -$12.35M $34.94M -$9.210M
Capital Expenditures $0.00 $0.00 $2.163K
Free Cash Flow -$12.35M $34.94M -$9.212M
YoY Change 82.42% -479.33% 148.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-61156 USD
CY2016Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-129737 USD
CY2017Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
137248 USD
CY2016Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
201827 USD
CY2017Q1 us-gaap Depreciation
Depreciation
31916 USD
CY2016Q1 us-gaap Depreciation
Depreciation
18558 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
34944909 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9210393 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
640017 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
42242926 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6712481 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27107526 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20395045 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-420948 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
962450 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-739261 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-796010 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
687497 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
61394 USD
CY2017Q1 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
13766 USD
CY2016Q1 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-7121 USD
CY2017Q1 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
76092 USD
CY2016Q1 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
72090 USD
CY2017Q1 asmb Accrued Offering Cost Related To Issuance Of Common Stock
AccruedOfferingCostRelatedToIssuanceOfCommonStock
640017 USD
CY2016Q1 asmb Accrued Offering Cost Related To Issuance Of Common Stock
AccruedOfferingCostRelatedToIssuanceOfCommonStock
0 USD
CY2017Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
CY2016Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7951257 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
6658000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2497912 USD
CY2017Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000 USD
CY2016Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000 USD
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
409285 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
409285 USD
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
226514 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
194598 USD
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1726245 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2884000 USD
CY2017Q1 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
980436 USD
CY2016Q4 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
916674 USD
CY2017Q1 asmb Accured General And Administrative Expenses Current
AccuredGeneralAndAdministrativeExpensesCurrent
1061853 USD
CY2016Q4 asmb Accured General And Administrative Expenses Current
AccuredGeneralAndAdministrativeExpensesCurrent
710412 USD
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
241737 USD
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
27287602 USD
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
26824156 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9610 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
473056 USD
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
20105000 USD
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
4901519 USD
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
18559 USD
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
8939618 USD
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
382698 USD
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
13841137 USD
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
401257 USD
CY2017Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1224647 USD
CY2017Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
640017 USD
CY2017Q1 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
76092 USD
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1224647 USD
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1459855 USD
CY2017Q1 asmb Future Stock Based Compensation Expense Total
FutureStockBasedCompensationExpenseTotal
11164646 USD
CY2017Q1 asmb Future Stock Based Compensation Expense Current
FutureStockBasedCompensationExpenseCurrent
5902782 USD
CY2017Q1 asmb Future Stock Based Compensation Expense Year Two
FutureStockBasedCompensationExpenseYearTwo
3811811 USD
CY2017Q1 asmb Future Stock Based Compensation Expense Year Three
FutureStockBasedCompensationExpenseYearThree
1112946 USD
CY2017Q1 asmb Future Stock Based Compensation Expense Year Four
FutureStockBasedCompensationExpenseYearFour
331969 USD
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
ASSEMBLY BIOSCIENCES, INC.
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001426800
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q1 dei Trading Symbol
TradingSymbol
ASMB
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17346103 shares
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4995894 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2017Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
44319737 USD
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 USD
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17318044 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17318044 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17246754 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17246754 shares
CY2016Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0 USD
CY2017Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
684369 USD
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
49315631 USD
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong>Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Significant estimates inherent in the preparation of the accompanying financial statements include recoverability and useful lives (indefinite or finite) of intangible assets, assessment of impairment of goodwill, and the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters. In addition, with the Company entering to the Collaboration Agreement, the Company believes its condensed consolidated financial statements are also impacted by the following accounting estimates and judgments: (i) identifying deliverables under&#160;collaboration agreements involving multiple elements and determining whether such deliverables are separable from other aspects of the contractual relationship; (ii) estimating the selling price of deliverables for the purpose of allocating arrangement consideration for revenue recognition; and (iii) estimating the periods over which the allocated consideration for deliverables is recognized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company&#8217;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company&#8217;s estimates and could cause actual results to differ from those estimates and assumptions.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1 us-gaap Licenses Revenue
LicensesRevenue
50000000 USD
CY2017Q1 asmb Futurestockbasedcompensationexpenseyearfive
Futurestockbasedcompensationexpenseyearfive
5138 USD
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11200000 USD
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
600000 USD
CY2017Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16909 shares
CY2017Q1 asmb Deferred Revenueamortization Period Over Service Tenure
DeferredRevenueamortizationPeriodOverServiceTenure
P10Y
CY2017Q1 asmb Sharebased Compensation Arrangement By Sharebased Payment Award Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitureRate
0 pure

Files In Submission

Name View Source Status
0001144204-17-024996-index-headers.html Edgar Link pending
0001144204-17-024996-index.html Edgar Link pending
0001144204-17-024996.txt Edgar Link pending
0001144204-17-024996-xbrl.zip Edgar Link pending
asmb-20170331.xml Edgar Link completed
asmb-20170331.xsd Edgar Link pending
asmb-20170331_cal.xml Edgar Link unprocessable
asmb-20170331_def.xml Edgar Link unprocessable
asmb-20170331_lab.xml Edgar Link unprocessable
asmb-20170331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v465414_10q.htm Edgar Link pending
v465414_ex10-1.htm Edgar Link pending
v465414_ex31-1.htm Edgar Link pending
v465414_ex31-2.htm Edgar Link pending
v465414_ex32-1.htm Edgar Link pending
v465414_ex32-2.htm Edgar Link pending